BIOMAT Database Logo BIOMAT Database Logo

Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. 1991

L S Austin, and R B Lydiard, and J C Ballenger, and B M Cohen, and M T Laraia, and J J Zealberg, and M D Fossey, and E H Ellinwood
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston 29425.

While many data suggest that Obsessive-Compulsive Disorder (OCD) is an illness accompanied by dysregulation of the serotonergic system, interesting clinical evidence and animal studies also suggest possible dysregulation of the dopaminergic (DA) system. In order to determine whether clomipramine (CMI), an antiobsessional agent, is capable of altering DA function, we performed a neuroleptic radioreceptor assay (NRRA) on plasma samples from OCD patients before and after treatment in a double-blind, placebo controlled trial of CMI. CMI produced mild but significant DA D-2 receptor binding activity in an in vitro assay. The degree of dopamine binding activity did not correlate with clinical response to clomipramine. Because it has been suggested that another drug with antiobsessional efficacy, fluoxetine, may also have dopamine blocking properties, it may be speculated that antidopaminergic activity in combination with serotonergic effects is involved in antiobsessional activity of effective agents for some patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009771 Obsessive-Compulsive Disorder An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension. Anankastic Personality,Neurosis, Obsessive-Compulsive,Anankastic Personalities,Disorder, Obsessive-Compulsive,Disorders, Obsessive-Compulsive,Neuroses, Obsessive-Compulsive,Neurosis, Obsessive Compulsive,Obsessive Compulsive Disorder,Obsessive-Compulsive Disorders,Obsessive-Compulsive Neuroses,Obsessive-Compulsive Neurosis,Personalities, Anankastic,Personality, Anankastic
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D002997 Clomipramine A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine. Chlorimipramine,Anafranil,Chlomipramine,Clomipramine Hydrochloride,Clomipramine Maleate (1:1),Clomipramine Monohydrochloride,Hydiphen,Hydrochloride, Clomipramine,Monohydrochloride, Clomipramine
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

L S Austin, and R B Lydiard, and J C Ballenger, and B M Cohen, and M T Laraia, and J J Zealberg, and M D Fossey, and E H Ellinwood
Clomipramine in obsessive-compulsive disorder.
September 1990, Biological psychiatry,
L S Austin, and R B Lydiard, and J C Ballenger, and B M Cohen, and M T Laraia, and J J Zealberg, and M D Fossey, and E H Ellinwood
Clomipramine in obsessive compulsive disorder.
April 1991, The Journal of clinical psychiatry,
L S Austin, and R B Lydiard, and J C Ballenger, and B M Cohen, and M T Laraia, and J J Zealberg, and M D Fossey, and E H Ellinwood
Clomipramine for obsessive compulsive disorder.
November 1988, The Medical letter on drugs and therapeutics,
L S Austin, and R B Lydiard, and J C Ballenger, and B M Cohen, and M T Laraia, and J J Zealberg, and M D Fossey, and E H Ellinwood
Clomipramine and obsessive-compulsive disorder.
January 1995, Journal of child and adolescent psychiatric nursing : official publication of the Association of Child and Adolescent Psychiatric Nurses, Inc,
L S Austin, and R B Lydiard, and J C Ballenger, and B M Cohen, and M T Laraia, and J J Zealberg, and M D Fossey, and E H Ellinwood
Clomipramine for obsessive-compulsive disorder.
May 1991, American family physician,
L S Austin, and R B Lydiard, and J C Ballenger, and B M Cohen, and M T Laraia, and J J Zealberg, and M D Fossey, and E H Ellinwood
Clomipramine use in obsessive-compulsive disorder.
November 2002, Expert review of neurotherapeutics,
L S Austin, and R B Lydiard, and J C Ballenger, and B M Cohen, and M T Laraia, and J J Zealberg, and M D Fossey, and E H Ellinwood
Clomipramine in resistant obsessive compulsive disorder.
October 1988, Indian journal of psychiatry,
L S Austin, and R B Lydiard, and J C Ballenger, and B M Cohen, and M T Laraia, and J J Zealberg, and M D Fossey, and E H Ellinwood
Plasma clomipramine levels in adult patients with obsessive-compulsive disorder.
January 2012, International clinical psychopharmacology,
L S Austin, and R B Lydiard, and J C Ballenger, and B M Cohen, and M T Laraia, and J J Zealberg, and M D Fossey, and E H Ellinwood
Efficacy of clomipramine in obsessive-compulsive disorder.
January 1996, Anxiety,
L S Austin, and R B Lydiard, and J C Ballenger, and B M Cohen, and M T Laraia, and J J Zealberg, and M D Fossey, and E H Ellinwood
Intravenous clomipramine for obsessive-compulsive disorder.
June 1994, Journal of clinical psychopharmacology,
Copied contents to your clipboard!